stem cell therapy also bring great promises for the disease, however, there is still a long way. [5] [6] [7] So the disease prevention is still the key, especially screening of female carrier and prenatal diagnosis.
The diagnosis of DMD relies on postnatal genetic testing using MLPA analysis, 8 DHPLC 9, 10 or next-generation sequencing technology 11, 12 or direct sequencing methods. 13 Performing prenatal diagnosis can offer sufficient and valuable genetic information for DMD families, to make appropriate reproductive choices. Prenatal molecular diagnosis for DMD was firstly introduced by the Netherlands in 1985. 14 At present, multiplex PCR, MLPA, and other techniques were tested to make prenatal diagnosis. [15] [16] [17] However, there are also barriers associated with prenatal diagnosis of DMD, which include probands and carries screening, pre and post-test counseling, and early completion of fetal diagnosis. In this study, we retrospectively analyzed clinical data on 237 DMD cases and the clinical application of DHPLC and direct Sanger sequencing in DMD families and assessed the validity of the strategy.
| MATERIAL S AND ME THODS

| Subjects
The study was approved by the Chinese People Liberation Army 
| Karyotype analysis
Amniocentesis was performed under ultrasonographic guidance.
Amniotic fluid samples (20 mL) were collected and centrifuged at 395 g for 8 minutes. After discarding the supernatant, the cells were suspended in 6 mL culture medium (GIBCO AmnioMAX-II complete, Grand Island, NY, USA) and cultured for 9 days at 37°C and 5%
CO2. 18 Karyotype analysis was performed to exclude fetal abnormal karyotype.
| Gene mutation examination
Genomic DNA was extracted from peripheral blood specimens or fetal samples using the NP986-S nucleic acid extraction system (Tian Long, Xi'an, China). The major rearrangement of DMD gene was examined by denaturing high-performance liquid chromatography (DHPLC) and multiplex PCR (mPCR). The copy number variation of samples was performed according to Zou et al. 10 If a large deletion/ duplication was not detected by DHPLC and multiplex PCR, PCR amplification, and Sanger sequencing using primer sets were used to confirm the diagnosis. The mutations were described according to the Leiden Muscular Dystrophy database (http://www.dmd.nl/). The nomenclature system was in 2000 on human mutation (reference sequence GenBank fileNM_004006.1). 19 
| Gene mutation analysis
For prenatal diagnosis of monogenic disorders, thirteen STR markers within the dystrophin gene were applied to rule out maternal contamination (markers AMEL, D3S1358, D5S818, D8S1179,   D13S317, D16S539, D18S51, D21S11, FGA, CSF1PO, TPOX, VWA, and TH01).
These sequences were analyzed by preliminary comparison with sequences in the GenBank database and software Vector NTI.
The nucleotide position was assessed using the DMD reference sequence (RefSeq NM_004006.2) and mutation nomenclature 
| Genetic counseling and follow-up
All pregnant women received counseling by genetic counselor according to a standardized protocol consistent with national guidelines. 21 The pregnancy outcomes were acquired from delivery records if the pregnant women were delivered at our hospital; otherwise, they were gained by telephone follow-up.
| Statistical analysis
Statistical analyses for clinical data were performed using GraphPad Prism 5 software (GraphPad Software, La Jolla, CA). Between-group comparisons were calculated using a chi-square test. All values are described as mean ± SD. For all tests, P-value less than .05 was considered as significant difference. 
| Mutation spectrum
The diagnostic process and spectrum of mutations of 237 DMD families were summarized as a flowchart in Figure DMD different mutations were found in 237 cases. 
| Detection and duplication mutations
| Small mutations
| Analysis the association between the age of onset and mutation patterns
According to clinical data, the mean age at loss of ambulation among deletion, duplication, and small mutation were 4.7 ± 2.2, 4.3 ± 1.9, and 4.2 ± 1.9 years, respectively. No relationships were found between the age of onset and mutation patterns (P > .05).
| Prenatal diagnosis of 237 fetuses
For 237 families, we analyzed the carrier status of all pregnant women, among whom 131 had the same mutation as their children 
+, positive for DMD mutation; −, negative for DMD mutation; C, carrier for DMD; Top, termination of pregnancy.
or patients. Fourteen pathogenic mutations and 18 female carriers were detected in fetal samples ( 
| Follow-up and genetic counseling
Among the total cases, 14 pregnant women chose the termination of pregnancy. The pedigree diagnosed as negative and carriers continued the pregnancy. In total, the pregnancies of 14 cases were interrupted, 2 were preterm births (>34 gestational weeks), 151 were delivered at term, 63 continued the pregnancy and 7 were lost to follow-up. For 18 female carrier fetuses, long time monitoring is necessary.
| D ISCUSS I ON
Lacking effective therapies, DMD brings great harm to many patients and their families. Families with DMD history showed anxiety and depression and strongly requested prenatal diagnosis. It has been known that 1/3 sporadic mutations of DMD gene occurs in male patients. 23, 24 Germinal mosaicism cases were detected in some DMD families. [25] [26] [27] [28] So, the prenatal DMD diagnosis has been recommended as the most effective way to avoid congenital malformed children. In this retrospective cohort study, genetic analysis and prenatal diagnosis results of the 237 Chinese families with DMD history were presented. Fourteen pathogenic mutations (5.9%) and 18 female carriers (7.6%) were detected in fetal samples. The size of the samples was good for a rare disorder.
Molecular genetic analysis of DMD patients is essential for establishing a definitive diagnosis, directing appropriate clinical management, and providing for further prenatal diagnosis, and genetic counseling. 29 Cho A et al reported that the rates of deletions, duplications, and sequence variations were reported as 65.4%, 13.3%, and 12.3%, respectively. 22 Chen C et al reported that they were 79%, 19.8%, and 9.2%, respectively. 9 In our study, we found the rate of deletions, duplications, and sequence variations as 47.3%, 8.4%, 1.7%, and 42.6%, respectively. We believed that these differences between the rates were due to sample size for inspection patients and regional differences.
In recent years, the prenatal diagnosis techniques acquired great improvements. The advancement in ultrasound-monitored amniocentesis enhanced the capability for diagnosis of DMD in utero.
TA et al 30 reported combination of STR and MLPA could be a rapid, reliable, and affordable detection protocol for determination of the carrier's status and prenatal diagnosis of DMD. 30 Zhang et al 31 reported that real-time PCR assay was successfully used to make prenatal diagnosis of DMD families in thirty Chinese families. 31 Yoo et al reported the single targeted sequencing platform was applied to detect carriers and make non-invasive prenatal diagnosis. 17 Parks et al reported that haplotype dosage analysis for X-linked disorders was one non-invasive prenatal diagnosis for DMD. 32 Therefore, we identified DMD mutations in a cohort of 237 Chinese patients using denaturing high-performance liquid chromatography (DHPLC)
followed by Sanger sequencing according to local conditions and platforms in our prenatal diagnosis center. Chen et al (2014) 29 also
reported DHPLC analysis exhibited high efficiency and specificity for identifying any small alterations in the DMD gene. 9 In this study, 82 different small mutations were previously reported or possibly affect the DMD gene function (Table 1) . However, the pathogenicity of six different small mutations (p.Asp556Asn, p.Gly882Asp, p.Gln2366Lys, p.Gln2806Arg, c.5586 + 18A>G, and c.9649 + 15T>C) was not clear.
This study offered 4-year clinical prenatal diagnosis experience of Duchenne muscular dystrophy, which was one relatively large sample size to perform mutational analysis. The limitation of this study was that some novel mutations had not been fully proved to be related to the DMD.
In conclusion, this study offers informative data for proper prenatal genetic counseling of pregnant women and their partner.
DHPLC technology has high sensitivity and specificity.
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